NOTE: The below is pure speculation on my part that RenovoRx...

NOTE: The below is pure speculation on my part that RenovoRx could be a vehicle candidate for an Imugene NASDAQ listing or parts thereof.

The Collaboration recently announced will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform.

TAMP is expected to enable localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors.

Disclosure: NASDAQ : RNXT not held.

RNXT in $US (default plot, white)/IMU pair directional comparison.
IMO DYOR not advice in any form.